Dyno Therapeutics Launches Dyno eCap 1 Vector, a Field-Leading AAV Capsid for Eye Gene Therapies - Yahoo Finance
| 185490 Stock | KRW 2,825 5.00 0.18% |
About 62% of EyeGene's investor base is looking to short. The analysis of current outlook of investing in EyeGene suggests that many traders are alarmed regarding EyeGene's prospects. The current market sentiment, together with EyeGene's historical and current headlines, can help investors time the market. In addition, many technical investors use EyeGene stock news signals to limit their universe of possible portfolio assets.
EyeGene |
Dyno Therapeutics Launches Dyno eCap 1 Vector, a Field-Leading AAV Capsid for Eye Gene Therapies Yahoo Finance
Read at news.google.com
 |
EyeGene Fundamental Analysis
We analyze EyeGene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of EyeGene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of EyeGene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
EyeGene is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
EyeGene Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with EyeGene stock to make a market-neutral strategy. Peer analysis of EyeGene could also be used in its relative valuation, which is a method of valuing EyeGene by comparing valuation metrics with similar companies.
Peers
EyeGene Related Equities
| 003230 | Samyang Foods | 0.76 |
| ||
| 011155 | CJ Seafood | 1.17 |
| ||
| 118000 | Chorokbaem Healthcare | 1.59 |
| ||
| 071200 | INFINITT Healthcare | 2.39 |
| ||
| 031440 | Shinsegae Food | 3.08 |
| ||
| 036220 | Osang Healthcare | 3.61 |
| ||
| 246960 | InnoTherapy | 3.90 |
|
Complementary Tools for EyeGene Stock analysis
When running EyeGene's price analysis, check to measure EyeGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EyeGene is operating at the current time. Most of EyeGene's value examination focuses on studying past and present price action to predict the probability of EyeGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EyeGene's price. Additionally, you may evaluate how the addition of EyeGene to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |